Warner Chilcott Ltd.'s (WCRX) announced first-quarter EPS, excluding items, of 39 cents, which matched the consensus.

Revenues expanded 7% to $246 million, primarily due to the growth of Doryx, Loestrin 24 FE and Estrace Cream.

Warner Chillcott indicated that it continues to expect fiscal 2009 revenues to range between $1.015 billion and $1.025 billion.

The developer of woman healthcare products also affirmed full-year earnings guidance of $1.55 to $1.60 per share, excluding items, which is in-line with the $1.59 consensus derived from 12 analysts.

WCRX, Zacks #3 Rank ("Hold") stock, is about breakeven today with volume of approximately 616,000, which is lower than the average daily volume of about 1.02 million.

"WCRX" Free Stock Analysis: Buy? Sell? Hold?Zacks Investment Research